IBL HealthCare Posts Profit Growth in FY2026 as Revenue and Cash Position Improve

Karachi, September 24, 2026: IBL HealthCare Limited has announced its financial results for the year ended June 30, 2026, reporting an increase in revenue and profit compared with the previous year.

According to the company’s financial results submitted to the Pakistan Stock Exchange, the Board of Directors met on September 23, 2026, and recommended no cash dividend, bonus shares or right shares for the year under review.

Revenue rises to Rs4.61 billion

IBL HealthCare recorded revenue from contracts with customers of Rs4.607 billion during FY2026, compared with Rs4.322 billion in FY2025. This represents an increase of around 6.6%.

The company’s cost of sales increased to Rs2.962 billion from Rs2.875 billion, while gross profit improved to Rs1.645 billion, compared with Rs1.447 billion a year earlier.

Profit after tax reaches Rs220.4 million

The company reported profit before income tax of Rs401.3 million for FY2026, compared with Rs340.2 million in the previous year after accounting for the levy.

After an income tax expense of Rs180.9 million, IBL HealthCare posted profit after taxation of Rs220.4 million, up from Rs208.4 million in FY2025. Earnings per share also increased to Rs2.24 from Rs2.11.

The improvement in profitability came despite higher marketing and distribution expenses, which rose to approximately Rs1.006 billion from Rs858.4 million. Finance costs, meanwhile, declined to Rs42.9 million from Rs60.2 million.

Stronger cash position

IBL HealthCare also reported a significant improvement in its cash position during the year.

Net cash generated from operating activities stood at Rs659.2 million, compared with a net operating cash outflow of Rs259.7 million in FY2025. After investing and financing activities, the company ended the year with cash and cash equivalents of Rs727.2 million, substantially higher than Rs208.9 million at the end of the previous year.

The balance sheet showed total assets of approximately Rs4.034 billion as of June 30, 2026, compared with Rs4.010 billion a year earlier. Share capital increased to Rs985.3 million from Rs856.7 million, while total equity and reserves reached approximately Rs2.543 billion.

No dividend announced for shareholders

Despite the improvement in earnings and operating cash generation, the company’s board recommended nil cash dividend for FY2026. It also recommended no bonus shares or right shares and announced no other corporate action.

The statement of changes in equity shows that the company’s issued and paid-up share capital increased during the year following the issuance of bonus shares, with the balance reaching Rs985.26 million as of June 30, 2026.

Outlook

IBL HealthCare’s FY2026 results show a year of higher revenue, improved profitability and a substantially stronger operating cash position. The company’s annual report for the year ended June 30, 2026, is expected to be transmitted through PUCARS within the specified timeframe.

Overall, the financial statements indicate that IBL HealthCare closed FY2026 with revenue of Rs4.61 billion, profit after tax of Rs220.4 million and cash balances of Rs727.2 million, while shareholders will not receive a cash dividend for the year.